Reach US_340B_DRUG_PRICING readiness without rebuilding your policy programme
The 340B Drug Pricing Program requires drug manufacturers participating in Medicaid to provide discounted outpatient drugs to eligible health care organisations (covered entities) — DSH hospitals, Children's hospitals, FQHCs, Ryan White clinics + others. HRSA administers the program with audit authority. Compliance requires patient definition, GPO prohibition, duplicate discount prohibition, registration + recertification, contract pharmacy management + data integrity. Manufacturer recoveries on findings are material; HRSA + manufacturer audit findings increasingly involve contract-pharmacy + Medicaid duplicates. Quick Policy maps US_340B_DRUG_PRICING into the policy families, controls, and evidence your team needs — and keeps it current between audits.
US_340B
Framework
US
Jurisdiction
Supervisory
Assurance
365 days
Review cadence
US_340B_DRUG_PRICING quick answer
Standard facts
Framework: US_340B
Authority: US Health Resources and Services Administration (HRSA)
Jurisdiction: US
Why US_340B_DRUG_PRICING matters for your operating model
US_340B_DRUG_PRICING doesn't just dictate document templates — it shapes which controls auditors test, what evidence they ask for, and which gaps surface first during diligence. Getting it wrong creates renewal slippage, audit findings, and stalled customer deals.
- • Issued by US Health Resources and Services Administration (HRSA) and primarily enforced in US.
- • Directly shapes policy families including Compliance Program, Pharmacy — these are the artefacts assessors open first.
- • Common artifacts include Policy.
- • Obligation model: Mandatory In Scope — meaning you need defensible reasoning for in-scope vs out-of-scope decisions, not just signed policies.
How Quick Policy helps you stand up US_340B_DRUG_PRICING
The platform turns US_340B_DRUG_PRICING from a PDF of requirements into a live operating model — policies, training, evidence, and audit-export packs that update in lock-step when the standard or your business changes.
- • Adopt US_340B_DRUG_PRICING once and Quick Policy seeds the right policy families (Compliance Program, Pharmacy) with applicability rationale your auditor can follow.
- • Common artifacts include Policy.
- • Review cadence is enforced at ~365 days so policies don't silently expire ahead of recertification.
- • Standard updates (US_340B_DRUG_PRICING revisions, errata, regulator guidance) trigger an applicability re-check across your active policies — not a full rewrite.
Policy families commonly involved
Recommended artifacts and context
Industry tags: LIFE_SCIENCES
Obligation model: Mandatory In Scope
Coverage depth: Profile
How Quick Policy operationalizes US_340B_DRUG_PRICING
Turn standards context into drafting, review, training, and evidence workflows that are easier to maintain over time.
Capture Core Profile
Admins complete adaptive onboarding to establish operating model, risk posture, and compliance objectives.
Determine Applicable Standards
Standards applicability ranks obligations by industry, geography, services, and data profile.
Generate and Harmonise Policy
Three-pass generation drafts, repairs contradictions, and validates coverage before reviewer handoff.
Review and Approve
Approvers validate policy language, mappings, and obligations using structured workflow stages.
Need adjacent guidance?
Use these pages for broader platform, industry, or buying context around US_340B_DRUG_PRICING.